Regulation of brain polyunsaturated fatty acid uptake and turnover

Svennerholm, 1964, The distribution of lipids in the human nervous system. I. Analytical procedure. Lipids of foetal and newborn brain, J. Neurochem., 11, 839, 10.1111/j.1471-4159.1964.tb06735.x Brenna, 2007, The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition, Prostaglandins Leukotrienes Essent. Fatty Acids, 77, 247, 10.1016/j.plefa.2007.10.016 M.A. Crawford, A.J. Sinclair, Nutritional influences in the evolution of mammalian brain, in: Lipids, Malnutrition and the Developing Brain, Ciba Foundation Symposium, 1971, pp. 267–292. Axelrod, 1990, Receptor-mediated activation of phospholipase A2 and arachidonic acid release in signal transduction, Biochem. Soc. Trans., 18, 503, 10.1042/bst0180503 Kim, 2007, Novel metabolism of docosahexaenoic acid in neural cells, J. Biol. Chem., 282, 18661, 10.1074/jbc.R700015200 Orr, 2008, The emerging role of docosahexaenoic acid in neuroinflammation, Curr. Opinion Invest. Drugs, 9, 735 Bazan, 2005, Lipid signaling in neural plasticity, brain repair, and neuroprotection, Mol. Neurobiol., 32, 89, 10.1385/MN:32:1:089 Rao, 2007, n-3 Polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism, Mol. Psychiatry, 12, 36, 10.1038/sj.mp.4001888 Akbar, 2005, Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival, Proc. Natl. Acad. Sci. USA, 102, 10858, 10.1073/pnas.0502903102 Bosetti, 2007, Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models, J. Neurochem., 102, 577, 10.1111/j.1471-4159.2007.04558.x Calon, 2007, Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies, Prostaglandins Leukotrienes Essent. Fatty Acids, 77, 287, 10.1016/j.plefa.2007.10.019 Freeman, 2006, Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry, J. Clin. Psychiatry, 67, 1954, 10.4088/JCP.v67n1217 Lands, 1976 Edmond, 2001, Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport, J. Mol. Neurosci., 16, 181, 10.1385/JMN:16:2-3:181 Polozova, 2006, Effect of docosahexaenoic acid on tissue targeting and metabolism of plasma lipoproteins, Prostaglandins Leukotrienes Essent. Fatty Acids, 75, 183, 10.1016/j.plefa.2006.05.009 Thies, 1992, Unsaturated fatty acids esterified in 2-acyl-l-lysophosphatidylcholine bound to albumin are more efficiently taken up by the young rat brain than the unesterified form, J. Neurochem., 59, 1110, 10.1111/j.1471-4159.1992.tb08353.x Rapoport, 2001, Delivery and turnover of plasma-derived essential PUFAs in mammalian brain, J. Lipid Res., 42, 678, 10.1016/S0022-2275(20)31629-1 Robinson, 1992, A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: review and critical analysis, Brain Res., 17, 187, 10.1016/0165-0173(92)90016-F Hamilton, 2007, A model for fatty acid transport into the brain, J. Mol. Neurosci., 33, 146, 10.1007/s12031-007-0050-3 Bazinet, 2005, Chronic valproate does not alter the kinetics of docosahexaenoic acid within brain phospholipids of the unanesthetized rat, Psychopharmacol. Berlin, 182, 180, 10.1007/s00213-005-0059-7 Bazinet, 2006, Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder, Biol. Psychiatry, 59, 401, 10.1016/j.biopsych.2005.07.024 Chang, 1999, Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment, Neurochem. Res., 24, 399, 10.1023/A:1020989701330 Chang, 1996, Lithium decreases turnover of arachidonate in several brain phospholipids, Neurosci. Lett., 220, 171, 10.1016/S0304-3940(96)13264-X Demar, 2006, Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats, Biochim. Biophys. Acta, 1761, 1050, 10.1016/j.bbalip.2006.06.006 Demar, 2005, Alpha-linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid, J. Neurochem., 94, 1063, 10.1111/j.1471-4159.2005.03258.x Igarashi, 2007, Docosahexaenoic acid synthesis from alpha-linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation, J. Lipid Res., 48, 1150, 10.1194/jlr.M600549-JLR200 Lee, 2008, Chronic N-methyl-d-aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat, J. Lipid Res., 49, 162, 10.1194/jlr.M700406-JLR200 Golovko, 2006, Uptake and metabolism of plasma-derived erucic acid by rat brain, J. Lipid Res., 47, 1289, 10.1194/jlr.M600029-JLR200 Contreras, 2000, Nutritional deprivation of alpha-linolenic acid decreases but does not abolish turnover and availability of unacylated docosahexaenoic acid and docosahexaenoyl-CoA in rat brain, J. Neurochem., 75, 2392, 10.1046/j.1471-4159.2000.0752392.x DeMar, 2006, One generation of n-3 polyunsaturated fatty acid deprivation increases depression and aggression test scores in rats, J. Lipid Res., 47, 172, 10.1194/jlr.M500362-JLR200 DeMar, 2004, Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids, J. Neurochem., 91, 1125, 10.1111/j.1471-4159.2004.02789.x J.S. Rao, R.N. Ertley, S.I. Rapoport, R.P. Bazinet, H.J. Lee, Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A(2) and its transcription factor, activator protein-2, J. Neurochem. (2007). Contreras, 2001, Chronic nutritional deprivation of n-3 alpha-linolenic acid does not affect n-6 arachidonic acid recycling within brain phospholipids of awake rats, J. Neurochem., 79, 1090, 10.1046/j.1471-4159.2001.00658.x Esposito, 2007, Imaging signal transduction via arachidonic acid in the human brain during visual stimulation by means of positron emission tomography, NeuroImage, 34, 1342, 10.1016/j.neuroimage.2006.11.018 G. Esposito, G. Giovacchini, J.S. Liow, et al., Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET, J. Nucl. Med. (2008). Chen, 2008, The low density lipoprotein receptor is not necessary for maintaining mouse brain polyunsaturated fatty acid concentrations, J. Lipid Res., 49, 147, 10.1194/jlr.M700386-JLR200 Oldendorf, 1977, The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat, Ann. Neurol., 1, 409, 10.1002/ana.410010502 Oldendorf, 1976, The large apparent metabolic work capacity of the blood–brain barrier, Trans. Am. Neurol. Assoc., 101, 157 Mashek, 2004, Revised nomenclature for the mammalian long-chain acyl-CoA synthetase gene family, J. Lipid Res., 45, 1958, 10.1194/jlr.E400002-JLR200 Milger, 2006, Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4, J. Cell Sci., 119, 4678, 10.1242/jcs.03280 DiRusso, 2005, Comparative biochemical studies of the murine fatty acid transport proteins (FATP) expressed in yeast, J. Biol. Chem., 280, 16829, 10.1074/jbc.M409598200 Jia, 2007, Fatty acid transport protein 4 is the principal very long chain fatty acyl-CoA synthetase in skin fibroblasts, J. Biol. Chem., 282, 20573, 10.1074/jbc.M700568200 MacDonald, 1991, Phospholipid fatty acid remodeling in mammalian cells, Biochim. Biophys. Acta, 1084, 105, 10.1016/0005-2760(91)90209-Z Shimizu, 1990, Arachidonic acid cascade and signal transduction, J. Neurochem., 55, 1, 10.1111/j.1471-4159.1990.tb08813.x Yang, 1999, Group-specific assays that distinguish between the four major types of mammalian phospholipase A2, Ann. Biochem., 269, 278, 10.1006/abio.1999.4053 Sun, 2004, Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases, J. Lipid Res., 45, 205, 10.1194/jlr.R300016-JLR200 Alonso, 1986, A cytosolic phospholipase in human neutrophils that hydrolyzes arachidonoyl-containing phosphatidylcholine, Biochim. Biophys. Acta, 878, 273, 10.1016/0005-2760(86)90156-6 Farooqui, 2000, Deacylation and reacylation of neural membrane glycerophospholipids, J. Mol. Neurosci., 14, 123, 10.1385/JMN:14:3:123 Green, 2008, The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids, J. Lipid Res., 49, 939, 10.1194/jlr.R700017-JLR200 Duncan, 2008, Identification and functional characterization of adipose-specific phospholipase A2 AdPLA, J. Biol. Chem., 283, 25428, 10.1074/jbc.M804146200 Cunnane, 2003, Why is carbon from some polyunsaturates extensively recycled into lipid synthesis?, Lipids, 38, 477, 10.1007/s11745-003-1087-8 Lee, 2007, Antimanic therapies target brain arachidonic acid signaling: lessons learned about the regulation of brain fatty acid metabolism, Prostaglandins Leukotrienes Essent. Fatty Acids, 77, 239, 10.1016/j.plefa.2007.10.018 Lee, 2005, Topiramate does not alter the kinetics of arachidonic or docosahexaenoic acid in brain phospholipids of the unanesthetized rat, Neurochem. Res., 30, 677, 10.1007/s11064-005-2756-3 Lee, 2006, Chronic fluoxetine increases cytosolic phospholipase A2 activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat, Psychopharmacol. Berlin, 190, 103, 10.1007/s00213-006-0582-1 H.J. Lee, J.S. Rao, L. Chang, S.I. Rapoport, R.P. Bazinet, Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder, Psychopharmacol. Berlin (2007). DeGeorge, 1991, Arecoline-stimulated brain incorporation of intravenously administered fatty acids in unanesthetized rats, J. Neurochem., 56, 352, 10.1111/j.1471-4159.1991.tb02603.x Serhan, 2005, Resolution of infammation: the beginning programs the end, Nat. Immunol., 6, 1191, 10.1038/ni1276 Schwab, 2007, Resolvin E1 and protectin D1 activate inflammation-resolution programmes, Nature, 447, 869, 10.1038/nature05877 Rao, 2008, Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?, Mol. Psychiatry, 13, 585, 10.1038/mp.2008.31 Rapoport, 2002, Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?, Arch. Gen. Psychiatry, 59, 592, 10.1001/archpsyc.59.7.592 Leslie, 2004, Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2, Prostaglandins Leukotrienes Essent. Fatty Acids, 70, 373, 10.1016/j.plefa.2003.12.012 Rintala, 1999, 85kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain, Neuroreport, 10, 3887, 10.1097/00001756-199912160-00030 Weerasinghe, 2004, The effect of chronic lithium on arachidonic acid release and metabolism in rat brain does not involve secretory phospholipase A2 or lipoxygenase/cytochrome P450 pathways, Brain Res. Bull., 63, 485, 10.1016/j.brainresbull.2004.04.005 Bosetti, 2002, Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain, Mol. Psychiatry, 7, 845, 10.1038/sj.mp.4001111 Rao, 2005, Decrease in the AP-2 DNA-binding activity and in the protein expression of AP-2 alpha and AP-2 beta in frontal cortex of rats treated with lithium for 6 Weeks, Neuropsychopharmacology, 30, 2006, 10.1038/sj.npp.1300740 Belmaker, 2004, Bipolar disorder, N. Engl. J. Med., 351, 476, 10.1056/NEJMra035354 Ghelardoni, 2004, Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain, Biol. Psychiatry, 56, 248, 10.1016/j.biopsych.2004.05.012 Rao, 2007, Chronic administration of carbamazepine downregulates AP-2 DNA binding activity and AP-2α protein expression in rat frontal cortex, Biol. Psychiatry, 61, 154, 10.1016/j.biopsych.2006.03.029 McElroy, 1992, Valproate in the treatment of bipolar disorder: literature review and clinical guidelines, J. Clin. Psychopharmacol., 12, 42S, 10.1097/00004714-199202001-00007 Chang, 2001, Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers, J. Neurochem., 77, 796, 10.1046/j.1471-4159.2001.00311.x Rao, 2007, Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kB DNA binding activity and COX-2 mRNA, Bipolar Disord., 9, 513, 10.1111/j.1399-5618.2007.00361.x Bosetti, 2003, Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain, J. Neurochem., 85, 690, 10.1046/j.1471-4159.2003.01701.x Laposata, 1985, Arachidonoyl-CoA synthetase. Separation from nonspecific acyl-CoA synthetase and distribution in various cells and tissues, J. Biol. Chem., 260, 11016, 10.1016/S0021-9258(17)39141-X Bazinet, 2006, Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder, Psychopharmacology Berlin, 184, 122, 10.1007/s00213-005-0272-4 Wong, 2005, Case history: the discovery of fluoxetine hydrochloride (Prozac), Nat. Rev., 4, 764 Yatham, 2005, Canadian network for mood and anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies, Bipolar Disord., 7, 5, 10.1111/j.1399-5618.2005.00219.x Rao, 2006, Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex, Pharmacogenomics J., 6, 413, 10.1038/sj.tpj.6500391 Dumuis, 1988, NMDA receptors activate the arachidonic acid cascade system in striatal neurons, Nature, 336, 68, 10.1038/336068a0 Sanacora, 2008, Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders, Nat. Rev., 7, 426, 10.1038/nrd2462 Rao, 2007, Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A(2) and its transcription factor, activator protein-2, J. Neurochem., 106, 1918, 10.1111/j.1471-4159.2007.04648.x Marcotte, 1998, Use of topiramate, a new anti-epileptic as a mood stabilizer, J. Affect Disord., 50, 245, 10.1016/S0165-0327(98)00110-4 McElroy, 2003, Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial, Am. J. Psychiatry, 160, 255, 10.1176/appi.ajp.160.2.255 Vieta, 2003, Adjunctive topiramate in bipolar II disorder, World J. Biol. Psychiatry, 4, 172, 10.1080/15622970310029915 Ghelardoni, 2005, Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism, Psychopharmacology Berl, 180, 523, 10.1007/s00213-005-2189-3 York, 2000, Effect of topiramate on body weight and body composition of Osborne–Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs, Nutrition, 16, 967, 10.1016/S0899-9007(00)00451-2 Kushner, 2006, Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials, Bipolar Disord., 8, 15, 10.1111/j.1399-5618.2006.00276.x Calabrese, 2005, New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder, Eur. Psychiatry, 20, 92, 10.1016/j.eurpsy.2004.12.003 Lee, 2008, Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex, Neurochem. Res., 33, 861, 10.1007/s11064-007-9526-3 Strokin, 2007, Prostaglandin synthesis in rat brain astrocytes is under the control of the n-3 docosahexaenoic acid, released by group VIB calcium-independent phospholipase A(2), J. Neurochem., 1, 1771, 10.1111/j.1471-4159.2007.04663.x